WO1999016460A3 - Apolipoprotein e/growth factor complexes and methods of use - Google Patents
Apolipoprotein e/growth factor complexes and methods of use Download PDFInfo
- Publication number
- WO1999016460A3 WO1999016460A3 PCT/US1998/020591 US9820591W WO9916460A3 WO 1999016460 A3 WO1999016460 A3 WO 1999016460A3 US 9820591 W US9820591 W US 9820591W WO 9916460 A3 WO9916460 A3 WO 9916460A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- apolipoprotein
- methods
- growth factor
- complexes
- neurotrophin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU96765/98A AU9676598A (en) | 1997-09-30 | 1998-09-29 | Apolipoprotein e/growth factor complexes and methods of use |
EP98950816A EP1019081A2 (en) | 1997-09-30 | 1998-09-29 | Apolipoprotein e/growth factor complexes and methods of use |
JP2000513594A JP2001518449A (en) | 1997-09-30 | 1998-09-29 | Apolipoprotein E / growth factor complex and uses thereof |
CA002304720A CA2304720A1 (en) | 1997-09-30 | 1998-09-29 | Apolipoprotein e/growth factor complexes and methods of use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6053397P | 1997-09-30 | 1997-09-30 | |
US60/060,533 | 1997-09-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999016460A2 WO1999016460A2 (en) | 1999-04-08 |
WO1999016460A3 true WO1999016460A3 (en) | 1999-06-17 |
Family
ID=22030099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/020591 WO1999016460A2 (en) | 1997-09-30 | 1998-09-29 | Apolipoprotein e/growth factor complexes and methods of use |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1019081A2 (en) |
JP (1) | JP2001518449A (en) |
AU (1) | AU9676598A (en) |
CA (1) | CA2304720A1 (en) |
WO (1) | WO1999016460A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19745950A1 (en) * | 1997-10-17 | 1999-04-22 | Dds Drug Delivery Service Ges | Drug carrier particle for site specific drug delivery, especially to CNS |
AR035016A1 (en) * | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | COMPOSITION OF AZOL PROMOTER OF PRODUCTION / SECRETION OF NEUROTROFINE, COMPOSITE PRODROGA OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THE SAME TO PREPARE THIS LAST. |
US20040120925A1 (en) * | 2001-03-12 | 2004-06-24 | Masahiro Toda | Remedies for nerve damages |
GB0329254D0 (en) * | 2003-12-17 | 2004-01-21 | Univ Manchester | Treatment of viral infections |
CA2637707A1 (en) | 2006-02-02 | 2007-08-09 | Rinat Neuroscience Corporation | Methods for treating obesity by administering a trkb antagonist |
WO2017165515A1 (en) * | 2016-03-23 | 2017-09-28 | The Research Institute At Nationwide Children's Hospital | Stimulation of bone growth using apolipoprotein e |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985000974A1 (en) * | 1983-09-01 | 1985-03-14 | Hybritech Incorporated | Antibody compositions of therapeutic agents having an extended serum half-life |
US5364769A (en) * | 1990-09-25 | 1994-11-15 | Genentech, Inc. | Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production |
WO1995005845A1 (en) * | 1993-08-20 | 1995-03-02 | Syntex (U.S.A.) Inc. | Pharmaceutical formulations of nerve growth factor |
EP0731108A1 (en) * | 1995-03-10 | 1996-09-11 | Boehringer Mannheim Gmbh | Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes |
US5604202A (en) * | 1990-11-13 | 1997-02-18 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of NGF growth factors to treat drug-induced neuropathy |
-
1998
- 1998-09-29 EP EP98950816A patent/EP1019081A2/en not_active Withdrawn
- 1998-09-29 CA CA002304720A patent/CA2304720A1/en not_active Abandoned
- 1998-09-29 WO PCT/US1998/020591 patent/WO1999016460A2/en not_active Application Discontinuation
- 1998-09-29 AU AU96765/98A patent/AU9676598A/en not_active Abandoned
- 1998-09-29 JP JP2000513594A patent/JP2001518449A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985000974A1 (en) * | 1983-09-01 | 1985-03-14 | Hybritech Incorporated | Antibody compositions of therapeutic agents having an extended serum half-life |
US5364769A (en) * | 1990-09-25 | 1994-11-15 | Genentech, Inc. | Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production |
US5604202A (en) * | 1990-11-13 | 1997-02-18 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of NGF growth factors to treat drug-induced neuropathy |
WO1995005845A1 (en) * | 1993-08-20 | 1995-03-02 | Syntex (U.S.A.) Inc. | Pharmaceutical formulations of nerve growth factor |
EP0731108A1 (en) * | 1995-03-10 | 1996-09-11 | Boehringer Mannheim Gmbh | Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes |
Non-Patent Citations (2)
Title |
---|
GUTMAN C R ET AL: "Apolipoprotein E binds to and potentiates the biological activity of ciliary neurotrophic factor", JOURNAL OF NEUROSCIENCE, vol. 17, no. 16, 15 August 1997 (1997-08-15), pages 6114 - 6121, XP002086887 * |
HOLTZMAN D.M.: "Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 92, 1995, pages 9480 - 9484, XP002090818 * |
Also Published As
Publication number | Publication date |
---|---|
WO1999016460A2 (en) | 1999-04-08 |
CA2304720A1 (en) | 1999-04-08 |
EP1019081A2 (en) | 2000-07-19 |
AU9676598A (en) | 1999-04-23 |
JP2001518449A (en) | 2001-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1196444B8 (en) | Exendin-4 conjugates and their medical use | |
AU6331898A (en) | Forskohlin for promoting lean body mass | |
EP1234586A3 (en) | Hepatoselective pharmaceutical actives | |
CA2223433A1 (en) | Ob protein compositions and methods | |
HU883981D0 (en) | Process for the production of medical preparations with antiviral or antibacterial effect | |
GB9519661D0 (en) | Fatty acid treatment | |
EP0933995B8 (en) | Method of treating endothelial injury | |
CA2205557A1 (en) | Monofunctional and/or polyfunctional polylysine conjugates | |
CA2373794A1 (en) | Compositions and uses of et743 for treating cancer | |
CA2139385A1 (en) | Products containing g-csf and tnf binding protein | |
CA2144514A1 (en) | Morphogen-induced liver regeneration | |
AU7128296A (en) | Pharmaceutical combination preparations containing erythropoietin and iron preparations | |
WO1999062940A3 (en) | Methods of altering cardiac cell phenotype | |
DE69637825D1 (en) | S-NITROSOTHIOL-ENRICHED ERYTHROCYTES AND THEIR USE | |
WO1999016460A3 (en) | Apolipoprotein e/growth factor complexes and methods of use | |
CA2259152A1 (en) | Adenovirus e4 proteins for inducing cell death | |
AU3927189A (en) | N-2,3-butadienyl tri- and tetraaminoalkane derivatives | |
CA2094275A1 (en) | Methods and compositions for the treatment of cell proliferation disorders | |
CA2060560A1 (en) | Method for insuring adequate intracellular glutathione in tissue | |
CA2098113A1 (en) | Substances of polypeptide nature useful in human therapy | |
EP1304108A3 (en) | Anti-arrhythmic composition and methods of treatment | |
EP0857733A3 (en) | Hemoglobin having protecting ligands of oxygen binding positions as artificial oxygen carriers for direct biological or medicinal use and process for its preparation | |
CA2319542A1 (en) | The treatment of sexual dysfunction in certain patient groups | |
CA2283450A1 (en) | Methods for treatment of scar tissue | |
RU96124444A (en) | BIOLOGICAL COMPOSITION FOR THE TREATMENT OF THE RAS "COLLAHIT" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 96765/98 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2304720 Country of ref document: CA Ref country code: CA Ref document number: 2304720 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 513594 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998950816 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998950816 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998950816 Country of ref document: EP |